PDF下载 ( 1262 KB)
Current perspectives on immune pathogenesis and immune therapy of chronic hepatitis B
-
摘要:
<正>核苷类似物和干扰素等抗病毒药物已被广泛应用于慢性乙型肝炎(CHB)的临床治疗,并取得了一定疗效。然而现有的抗病毒药物虽可显著抑制HBV复制,但却不能完全清除体内的共价闭合环状DNA(cccDNA),难以持久恢复患者的抗病毒免疫功能,导致HBsAg长期存在。因此,要实现HBsAg血清学转化,清除慢性HBV感染患者体内cccDNA,必须依靠患者特异性抗病毒免疫能力的恢复。最近有研究表明,HBV隐匿
-
Key words:
- hepatitis B /
- chronic /
- hepatitis B virus
-
[1]Zerbini A, Pilli M, Boni C, et al.The characteristics of the cell-mediated immune response identify different profiles of occult hepa-titis B virus infection[J].Gastroenterology, 2008, 134 (5) :1470-1481. [2]Bes M, Vargas V, Piron M, et al.T cell responses and viral varia-bility in blood donation candidates with occult hepatitis B infection[J].J Hepatol, 2012, 56 (4) :765-774. [3]Michel ML, Deng Q, Mancini-Bourgine M.Therapeutic vaccines andimmune-based therapies for the treatment of chronic hepatitis B:per-spectives and challenges[J].J Hepatol, 2011, 54 (6) :1286-1296. [4]Jan RH, Lin YL, Chen LK, et al.Hepatitis B virus surface antigencan activate dendritic cells and modulate T helper type immune re-sponse[J].Microbiol Immunol, 2011, 55 (1) :51-59. [5]Boni C, Laccabue D, Lampertico P, et al.Restored Function ofHBV-Specific T Cells after Long-Term Effective Therapy withNucleos (t) ide Analogues[J].Gastroenterol, 2012, 143 (4) :963-973.e9. [6]Kanto T, Inoue M, Miyatake H, et al.Reduced numbers and im-paired ability of myeloid and plasmacytoid dendritic cells to polarizeT helper cells in chronic hepatitis C virus infection[J].J InfectDis, 2004, 190 (11) :1919-1926. [7]van der Molen RG, Sprengers D, Binda RS, et al.Functional im-pairment of myeloid and plasmacytoid dendritic cells of patients withchronic hepatitis B[J].Hepatology, 2004, 40 (3) :738-746. [8]Maini MK, Schurich A.The molecular basis of the failed immuneresponse in chronic HBV:therapeutic implications[J].J Hepatol, 2010, 52 (4) :616-619. [9] Stoop JN, van der Molen RG, Baan CC, et al.Regulatory T cellscontribute to the impaired immune response in patients with chronichepatitis B virus infection[J].Hepatology, 2005, 41 (4) :771-778. [10]Xu D, Fu J, Jin L, et al.Circulating and liver resident CD4+CD25+regulatory T cells actively influence the antiviral immune response anddisease progression in patients with hepatitis B[J].J Immunol, 2006, 177 (1) :739-747. [11]Manigold T, Racanelli V.T-cell regulation by CD4 regulatory Tcells during hepatitis B and C virus infections:facts and controver-sies[J].Lancet Infect Dis, 2007, 7 (12) :804-813. [12]Godkin A, Ng WF, Gallagher K, et al.Expansion of hepatitis C-specific CD4+CD25+regulatory T cells after viral clearance:amechanism to limit collateral damage?[J].J Allergy Clin Immu-nol, 2008, 121 (5) :1277-1284.e3. [13]Kared H, Lelievre JD, Donkova-Petrini V, et al.HIV-specificregulatory T cells are associated with higher CD4 cell counts in pri-mary infection[J].AIDS, 2008, 22 (18) :2451-2460. [14]Boni C, Fisicaro P, Valdatta C, et al.Characterization of hepatitisB virus (HBV) -specific T-cell dysfunction in chronic HBV in-fection[J].J Virol, 2007, 81 (8) :4215-4225. [15]Chen L, Zhang Z, Chen W, et al.B7-H1 up-regulation on mye-loid dendritic cells significantly suppresses T cell immune functionin patients with chronic hepatitis B[J].J Immunol, 2007, 178 (10) :6634-6641. [16]Schurich A, Khanna P, Lopes AR, et al.Role of the coinhibitoryreceptor cytotoxic T lymphocyte antigen-4 on apoptosis-ProneCD8 T cells in persistent hepatitis B virus infection[J].Hepatolo-gy, 2011, 53 (5) :1494-1503. [17]Wu W, Shi Y, Li S, et al.Blockade of Tim-3 signaling restoresthe virus-specific CD8 (+) T-cell response in patients withchronic hepatitis B[J].Eur J Immunol, 2012, 42 (5) :1180-1191. [18]Raziorrouh B, Schraut W, Gerlach T, et al.The immunoregulatoryrole of CD244 in chronic hepatitis B infection and its inhibitory po-tential on virus-specific CD8+T-cell function[J].Hepatology, 2010, 52 (6) :1934-1947. [19]Kassel R, Cruise MW, Iezzoni JC, et al.Chronically inflamed liv-ers up-regulate expression of inhibitory B7 family members[J].Hepatology, 2009, 50 (5) :1625-1637. [20]Zhang Z, Zhang JY, Wherry EJ, et al.Dynamic programmed death1 expression by virus-specific CD8 T cells correlates with the out-come of acute hepatitis B[J].Gastroenterology, 2008, 134 (7) :1938-1949, 1949.e1-3. [21]Wherry EJ, Ha SJ, Kaech SM, et al.Molecular signature of CD8+T cell exhaustion during chronic viral infection[J].Immunity, 2007, 27 (4) :670-684. [22]Kennedy P, Sandalova E, Jo J, et al.Preserved T-Cell Function inChildren and Young Adults With Immune-Tolerant Chronic HepatitisB[J].Gastroenterology, 2012, 143 (3) :637-645. [23]Lopes AR, Kellam P, Das A, et al.Bim-mediated deletion of an-tigen-specific CD8 T cells in patients unable to control HBV infec-tion[J].J Clin Invest, 2008, 118 (5) :1835-1845. [24]Das A, Hoare M, Davies N, et al.Functional skewing of the globalCD8 T cell population in chronic hepatitis B virus infection[J].JExp Med, 2008, 205 (9) :2111-2124. [25]Sandalova E, Laccabue D, Boni C, et al.Increased levels of argi-nase in patients with acute hepatitis B suppress antiviral T cells[J].Gastroenterology, 2012, 143 (1) :78-87.e3. [26]Bertoletti A, Ferrari C.Innate and adaptive immune responses inchronic hepatitis B virus infections:towards restoration of immunecontrol of viral infection[J].Gut, 2011. [27]Kakimi K, Guidotti LG, Koezuka Y, et al.Natural killer T cell ac-tivation inhibits hepatitis B virus replication in vivo[J].J ExpMed, 2000, 192 (7) :921-930. [28]Sitia G, Isogawa M, Iannacone M, et al.MMPs are required for re-cruitment of antigen-nonspecific mononuclear cells into the liver byCTLs[J].J Clin Invest, 2004, 113 (8) :1158-1167. [29]Kimura K, Kakimi K, Wieland S, et al.Interleukin-18 inhibitshepatitis B virus replication in the livers of transgenic mice[J].JVirol, 2002, 76 (21) :10702-10707. [30]Du J, Liang X, Liu Y, et al.Hepatitis B virus core protein inhibitsTRAIL-induced apoptosis of hepatocytes by blocking DR5 expres-sion[J].Cell Death Differ, 2009, 16 (2) :219-229. [31]Dunn C, Brunetto M, Reynolds G, et al.Cytokines induced duringchronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage[J].J Exp Med, 2007, 204 (3) :667-680. [32]Zhang Z, Zhang S, Zou Z, et al.Hypercytolytic activity of hepaticnatural killer cells correlates with liver injury in chronic hepatitis Bpatients[J].Hepatology, 2011, 53 (1) :73-85. [33]Fisicaro P, Valdatta C, Boni C, et al.Early kinetics of innate andadaptive immune responses during hepatitis B virus infection[J].Gut, 2009, 58 (7) :974-982. [34]Webster GJ, Reignat S, Maini MK, et al.Incubation phase of acutehepatitis B in man:dynamic of cellular immune mechanisms[J].Hepatology, 2000, 32 (5) :1117-1124. [35]Dunn C, Peppa D, Khanna P, et al.Temporal analysis of early im-mune responses in patients with acute hepatitis B virus infection[J].Gastroenterology, 2009, 137 (4) :1289-1300. [36]Eisenhardt M, Glassner A, Kramer B, et al.The CXCR3 (+) CD56Bright Phenotype Characterizes a Distinct NK Cell Subset withAnti-Fibrotic Potential That Shows Dys-Regulated Activity inHepatitis C[J].PLoS One, 2012, 7 (7) :e38846. [37]Muhanna N, Abu Tair L, Doron S, et al.Amelioration of hepaticfibrosis by NK cell activation[J].Gut, 2011, 60 (1) :90-98. [38]Glassner A, Eisenhardt M, Kramer B, et al.NK cells from HCV-infec-ted patients effectively induce apoptosis of activated primary human hepat-ic stellate cells in a TRAIL-, FasL-and NKG2D-dependent manner[J].Lab Invest, 2012, 92 (7) :967-977. [39]Kramer B, Korner C, Kebschull M, et al.NKp46 (High) expres-sion defines a NK cell subset that is potentially involved in control ofHCV replication and modulation of liver fibrosis[J].Hepatology, 2012, 56 (4) :1201-1213. [40]Gur C, Doron S, Kfir-Erenfeld S, et al.NKp46-mediated kill-ing of human and mouse hepatic stellate cells attenuates liver fibrosis[J].Gut, 2012, 61 (6) :885-893. [41]Heeg M, Thimme R.NK cells and hepatitis C:NKp46 expressionlinked to antiviral and antifibrotic activity[J].Hepatology, 2012, 56 (4) :1197-1200. [42]Chen W, Zhang Z, Shi M, et al.Activated plasmacytoid dendritic cellsact synergistically with hepatitis B core antigen-pulsed monocyte-de-rived dendritic cells in the induction of hepatitis B virus-specific CD8T-cell response[J].Clin Immunol, 2008, 129 (2) :295-303. [43]Topalian SL, Hodi FS, Brahmer JR, et al.Safety, activity, andimmune correlates of anti-PD-1 antibody in cancer[J].N Engl JMed, 2012, 366 (26) :2443-2454. [44]Brahmer JR, Tykodi SS, Chow LQ, et al.Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J].N Engl JMed, 2012, 366 (26) :2455-2465. [45]Ribas A.Tumor immunotherapy directed at PD-1[J].N Engl JMed, 2012, 366 (26) :2517-2519. [46]Bertoletti A, Gehring A.Therapeutic vaccination and novel strategies totreat chronic HBV infection[J].Expert Rev Gastroenterol Hepatol, 2009, 3 (5) :561-569. [47]Koh S, Bertoletti A.Viral hepatitis and serotonin:altering cytotoxicT-lymphocyte function in the liver[J].Expert Rev Vaccines, 2009, 8 (1) :29-32. [48]Morgan RA, Dudley ME, Wunderlich JR, et al.Cancer regressionin patients after transfer of genetically engineered lymphocytes[J].Science, 2006, 314 (5796) :126-129. [49]Zhang Z, Zhang JY, Wang LF, et al.Immunopathogenesis and prognos-tic immune markers of chronic hepatitis B virus infection[J].J Gastro-enterol Hepatol, 2012, 27 (2) :223-230. -
本文二维码
计量
- 文章访问数: 3562
- HTML全文浏览量: 10
- PDF下载量: 1322
- 被引次数: 0
下载:
